Skip Navigation
Search Menu
Find an Expert


John Joseph Laterra, M.D., Ph.D.

Photo of Dr. John Joseph Laterra, M.D., Ph.D.

Co-Director, Brain Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Professor of Neurology


Expertise: Brain Tumors, Neurology

Research Interests: Mechanisms of brain tumor malignancy


The Johns Hopkins Hospital
Appointment Phone: 410-614-3853

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Outpatient Center
Appointment Phone: 410-614-3853

601 N. Caroline St.
Baltimore, MD 21287 map


As Professor of Neurology, Oncology and Neuroscience and co-Director of the Brain Cancer Program at the Johns Hopkins Comprehensive Cancer Center, Dr. John Laterra focuses on the diagnosis and treatment of patients with primary brain tumors and neurological complications of systemic cancer.

Dr. Laterra is internationally recognized for his clinical expertise and research on mechanisms of brain tumor malignancy, tumor vascular biology and the identification of new therapeutic targets in gliomas. Dr. Laterra's research is funded by the National Institutes of Health and numerous private foundations. more


  • Co-Director, Brain Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  • Director, Division of Neuro-Oncology
  • Professor of Neurology
  • Professor of Neuroscience
  • Professor of Oncology

Departments / Divisions



  • MD, St. Vincent Charity Medical Center (1984)


  • University of Michigan Health System / Neurology (1988)

Board Certifications

  • American Board of Psychiatry & Neurology / Neurology-General (1990)

Research & Publications

Selected Publications

View all on Pubmed

Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting. Lukas RV, Wainwright DA, Laterra JJ. Future Oncol. 2016 Jan;12(2):143-7. doi: 10.2217/fon.15.299. Epub 2015 Nov 30.

Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems. Goodwin CR, Woodard CL, Zhou X, Pan J, Olivi A, Xia S, Bettegowda C, Sciubba DM, Pevsner J, Zhu H, Laterra J. Transl Oncol. 2016 Apr;9(2):124-9. doi: 10.1016/j.tranon.2016.02.001.

Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Xu X, Chan KW, Knutsson L, Artemov D, Xu J, Liu G, Kato Y, Lal B, Laterra J, McMahon MT, van Zijl PC. Magn Reson Med. 2015 Dec;74(6):1556-63. doi: 10.1002/mrm.25995. Epub 2015 Sep 25.

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J. Neuro Oncol. 2016 Apr;18(4):507-17. doi: 10.1093/neuonc/nov171. Epub 2015 Aug 27.

Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells. Lee EJ, Rath P, Liu J, Ryu D, Pei L, Noonepalle SK, Shull AY, Feng Q, Litofsky NS, Miller DC, Anthony DC, Kirk MD, Laterra J, Deng L, Xin HB, Wang X, Choi JH, Shi H. J Genet Genomics. 2015 Jul 20;42(7):355-71. doi: 10.1016/j.jgg.2015.06.003. Epub 2015 Jun 24.

Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Khattab MH, Marciscano AE, Lo SS, Lim M, Laterra JJ, Kleinberg LR, Redmond KJ. Case Rep Oncol Med. 2015;2015:431819. doi: 10.1155/2015/431819. Epub 2015 Jun 23.

Multi-echo length and offset VARied saturation (MeLOVARS) method for improved CEST imaging. Song X, Xu J, Xia S, Yadav NN, Lal B, Laterra J, Bulte JW, van Zijl PC, McMahon MT. Magn Reson Med. 2015 Feb;73(2):488-96. doi: 10.1002/mrm.25567. Epub 2014 Dec 16.

Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151. Tilghman J, Schiapparelli P, Lal B, Ying M, Quinones-Hinojosa A, Xia S, Laterra J. Neoplasia. 2016 Mar;18(3):185-98. doi: 10.1016/j.neo.2016.02.003.

Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Lesniak WG, Oskolkov N, Song X, Lal B, Yang X, Pomper M, Laterra J, Nimmagadda S, McMahon MT.Nano Lett. 2016 Apr 13;16(4):2248-53. doi: 10.1021/acs.nanolett.5b04517. Epub 2016 Mar 1.

A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis. Sun H, Luo L, Lal B, Ma X, Chen L, Hann CL, Fulton AM, Leahy DJ, Laterra J, Li M.Nat Commun. 2016 Feb 4;7:10339. doi: 10.1038/ncomms10339.

Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients. Xu X, Yadav NN, Knutsson L, Hua J, Kalyani R, Hall E, Laterra J, Blakeley J, Strowd R, Pomper M, Barker P, Chan K, Liu G, McMahon MT, Stevens RD, van Zijl PC. Tomography. 2015 Dec;1(2):105-114.

Extraneural Glioblastoma Multiforme Vertebral Metastasis. Goodwin CR, Liang L, Abu-Bonsrah N, Hdeib A, Elder BD, Kosztowski T, Bettegowda C, Laterra J, Burger P, Sciubba DM. World Neurosurg. 2015 Dec 15. pii: S1878-8750(15)01662-9. doi: 10.1016/j.wneu.2015.11.061. [Epub ahead of print] Review.

Activities & Honors


  • Jounral of Neuro-Oncology
    Associate Editor
  • Scientific Advisory Board of the American Brain Tumor Associaton
  • The Society of Neuro-Oncology
    Charter Member
Is this you? Edit Profile